Kortüm KM, Engelhardt M, Rasche L, Knop S, Einsele H (2013) Das multiple myelom. Der Internist 54:963–977

Article  PubMed  Google Scholar 

Tan CRC, Abdul-Majeed S, Cael B, Barta SK (2019) Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet 58:157–168

Article  CAS  PubMed  Google Scholar 

Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(Suppl 1):41–48

Article  CAS  PubMed  Google Scholar 

Voorhees PM, Dees EC, O’Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316–6325

CAS  PubMed  Google Scholar 

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431–440

Article  PubMed  Google Scholar 

Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA (2019) Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S52-s62

CAS  PubMed  Google Scholar 

Grammatico S, Cesini L, Petrucci MT (2016) Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood Lymphat Cancer 6:37–47

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D’Incalci M, De Coster R (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204:317–325

Article  CAS  PubMed  Google Scholar 

Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, Cavaletti G (2010) Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 14:343–350

Article  CAS  PubMed  Google Scholar 

Geisler S, Doan RA, Cheng GC, Cetinkaya-Fisgin A, Huang SX, Höke A, Milbrandt J, DiAntonio A (2019) Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight 4

Argyriou AA, Cavaletti G, Bruna J, Kyritsis AP, Kalofonos HP (2014) Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol 88:1669–1679

Article  PubMed  Google Scholar 

Perrot R, Berges R, Bocquet A, Eyer J (2008) Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 38:27–65

Article  CAS  PubMed  Google Scholar 

Meregalli C, Fumagalli G, Alberti P, Canta A, Carozzi VA, Chiorazzi A, Monza L, Pozzi E, Sandelius Å, Blennow K, Zetterberg H, Marmiroli P, Cavaletti G (2018) Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol 307:129–132

Article  CAS  PubMed  Google Scholar 

Lambertsen KL, Soares CB, Gaist D, Nielsen HH (2020) Neurofilaments: the C-reactive protein of neurology. Brain Sci 10:56

Article  CAS  PubMed  PubMed Central  Google Scholar 

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81:857–870

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, Alemany M, Kalofonou F, Alberti P, Dinoto A, Velissaris D, Stradella A, Cavaletti G, Ferrari S, Kalofonos HP (2022) Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. J Peripher Nerv Syst 27:166–174

Article  CAS  PubMed  Google Scholar 

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-548

Article  PubMed  Google Scholar 

Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72:596–601

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sommer C, Richter H, Rogausch JP, Frettlöh J, Lungenhausen M, Maier C (2011) A modified score to identify and discriminate neuropathic pain: a study on the German version of the neuropathic pain symptom inventory (NPSI). BMC Neurol 11:104

Article  PubMed  PubMed Central  Google Scholar 

Rolke R, Baron R, Maier C, Tölle TR, Treede DR, Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123:231–243

Article  CAS  PubMed  Google Scholar 

Magerl W, Krumova EK, Baron R, Tölle T, Treede RD, Maier C (2010) Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 151:598–605

Article  PubMed  Google Scholar 

Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle: principles and practice, 3rd edn. Oxford University Press, Oxford

Google Scholar 

International J-C Velcade® (Bortezomib) [SmPC], Beerse, Belgium: Janssen-Cilag International NV; (2021)

Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14(Suppl 4):iv45-54

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim SH, Choi MK, Park NY, Hyun JW, Lee MY, Kim HJ, Jung SK, Cha Y (2020) Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 10:7995

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgess BL, Cho E, Honigberg L (2022) Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep 12:15593

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, Maierhof SK, Hew L, Nolte L, Körtvelyessy P, Göpfert JC, Ruprecht K, Somps CJ, Blohmer JU, Sehouli J, Endres M, Boehmerle W (2022) Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7

Mortensen C, Steffensen KD, Simonsen E, Herskind K, Madsen JS, Olsen DA, Iversen DB, Bergmann TK, Pottegård A, Stage TB (2022) Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain

Velasco R, Argyriou AA, Marco C, Mariotto S, Stradella A, Hernández J, Pernas S, Ferrari S, Bruna J (2023) Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity. J Neurol 270:531–537

Article  CAS  PubMed  Google Scholar